Early Switch to Oral Antibiotics Is as Effective as Exclusive Intravenous Therapy for Infective Endocarditis

METHODOLOGY:

Researchers in France conducted a retrospective cohort study including 333 patients with infective endocarditis (median age, 71 years; 70% men) to determine the efficacy of switching to oral antibiotics after an initial intravenous course vs exclusive intravenous therapy alone.
Patients with at least 10 days of effective antibiotic therapy were assigned to either the exclusive intravenous group (n = 233) or the oral switch group (n = 100); the early switch to oral therapy was defined as transition within less than 10 days of starting effective intravenous treatment.
The primary outcome was treatment failure within 90 days after completing antibiotic therapy, with treatment failure being defined as death, recurrence with the same bacteria, or the need for secondary suppressive antibiotic therapy.
Secondary outcomes were the number of days alive and out of hospital during the 90-day period from treatment initiation and the occurrence of adverse events.

Overall, treatment failure occurred in 17.1% of patients, and treatment failure-free survival rates were significantly better in the oral switch group than in the exclusive intravenous group (10.0% vs 20.2%; P = .021).
No significant difference in treatment failure was observed between the oral switch therapy and exclusive intravenous treatment (hazard ratio, 0.55; 95% CI, 0.26-1.17).
Patients in the oral switch group spent significantly more days alive outside the hospital than those in the exclusive intravenous group (median, 59.0 vs 47.0 days; P = .001).
Rates of adverse events were similar in both the groups (P = .22).

Blood Pressure Variability Linked to Mortality in Patients With ANCA-Associated Vasculitis Among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis undergoing maintenance therapy, greater visit-to-visit systolic blood pressure variability (SBPV) was independently associated with an increased risk for all-cause mortality.

Morphine Underused for End-of-Life Dyspnea in the Emergency Department Compared with Inpatient Care Among 250 patients presenting to the emergency department (ED) with dyspnea at the end of life, 15.2% received morphine in the ED, whereas 68% received it during subsequent inpatient care. Patients with lung cancer or a do-not-resuscitate order were more likely to receive morphine in the ED, but its use was not associated with reduced survival.

Present state and future of screening for atrial fibrillation: a state-of-the-art review Atrial fibrillation is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains undiagnosed. Screening has been proposed to identify asymptomatic AF and initiate preventive treatment, but evidence for reduction in hard clinical endpoints such as stroke and heart failure remains inconclusive.

Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials Acute decompensated heart failure with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties.

Cardiovascular Benefits of Semaglutide in SELECT Trial Not Fully Explained by Weight Loss and Other Improvements In adults with obesity and established cardiovascular disease (CVD), semaglutide was associated with improvements in several risk factors. However, those changes only accounted for part of the reduced risk for major adverse cardiovascular events (MACE) noted in the SELECT trial.